<p>再生元制药（NASDAQ:REGN - 获取免费报告）在摩根士丹利发布的一份研究报告中，将其目标价格从 767.00 美元上调至 768.00 美元。该券商目前对这家生物制药公司的股票给予 “持平” 评级。摩根士丹利的目标价格表明，从公司当前价格来看，潜在上涨幅度为 4.12%。</p>
<ul>
<li>5 个医疗保健股票值得关注，因为行业轮动已全面展开</li>
</ul>
<p>其他一些研究公司也最近对 REGN 发表了评论。Truist Financial 在 11 月 24 日的报告中开始覆盖再生元制药。他们对该公司的评级为 “买入”，目标价格为 798.00 美元。Weiss Ratings 在周一的报告中重新发布了对再生元制药的 “持有（c）” 评级。华尔街 Zen 在 11 月 17 日的报告中将再生元制药的评级从 “持有” 上调至 “买入”。Guggenheim 在 10 月 29 日的研究报告中将再生元制药的目标价格从 815.00 美元上调至 865.00 美元，并给予该公司 “买入” 评级。最后，Cantor Fitzgerald 在 10 月 29 日的报告中将再生元制药的目标价格从 678.00 美元上调至 740.00 美元，并给予该股票 “超配” 评级。三位投资分析师给予该股票 “强烈买入” 评级，十五位分析师给予 “买入” 评级，九位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，再生元制药的共识评级为 “适度买入”，共识目标价格为 779.45 美元。</p>
<p><strong>查看我们关于 REGN 的最新研究报告</strong></p>
<h2>再生元制药股价下跌 1.2%</h2>
<ul>
<li>大跌者：3 只接近一年低点的股票，可能在 2025 年大幅上涨</li>
</ul>
<p>再生元制药的股票在周五的午盘交易中下跌了 9.22 美元，跌至 737.58 美元。该股票的交易量为 233,919 股，而其平均交易量为 1,096,572 股。再生元制药的 52 周低点为 476.49 美元，52 周高点为 790.98 美元。该公司的速动比率为 3.33，流动比率为 4.06，债务股本比率为 0.09。该股票的市值为 775.2 亿美元，市盈率为 17.66，市盈增长比率为 2.08，贝塔值为 0.37。该公司的 50 日简单移动平均线为 661.61 美元，200 日简单移动平均线为 591.76 美元。</p>
<p>再生元制药（NASDAQ:REGN - 获取免费报告）最近一次发布财报是在 10 月 28 日，生物制药公司报告该季度每股收益为 11.83 美元，超出市场共识预期的 9.73 美元，超出幅度为 2.10 美元。该公司该季度的收入为 37.5 亿美元，而分析师预期为 35.7 亿美元。再生元制药的股本回报率为 13.76%，净利润率为 32.13%。该公司该季度的收入同比增长 0.9%。在去年同期，该公司每股收益为 12.46 美元。股票研究分析师预计再生元制药在当前财政年度将发布 35.92 美元的每股收益。</p>
<h2>再生元制药的内部交易</h2>
<ul>
<li>2025 年值得购买的最佳生物技术股票</li>
</ul>
<p>在相关消息中，董事 Christine A. Poon 在 10 月 29 日的交易中出售了 6,500 股公司的股票。该股票的平均售价为 654.27 美元，总交易额为 4,252,755.00 美元。交易完成后，该董事直接持有公司 2,352 股股票，价值 1,538,843.04 美元。此次交易使其持股减少了 73.43%。该交易已在向证券交易委员会的备案中披露，相关信息可通过此链接获取。此外，副总裁 Jason Pitofsky 在 11 月 7 日的交易中出售了 431 股公司的股票。该股票的平均售价为 651.43 美元，总价值为 280,766.33 美元。交易完成后，该副总裁持有公司 4,233 股股票，价值 2,757,503.19 美元。此次交易使其持股减少了 9.24%。该销售的 SEC 备案提供了更多信息。公司内部人士持有公司 7.02% 的股票。</p>
<h2>对再生元制药的对冲基金看法</h2>
<p>几家机构投资者和对冲基金最近对 REGN 的持仓进行了调整。Allworth Financial LP 在第三季度将其在再生元制药的持股增加了 50.5%。Allworth Financial LP 目前持有 1,496 股生物制药公司的股票，价值 841,000 美元，此前在上个季度购买了 502 股。IFP Advisors Inc 在第三季度将其在再生元制药的持股增加了 14.2%。IFP Advisors Inc 目前持有 1,405 股生物制药公司的股票，价值 790,000 美元，此前在上个季度增加了 175 股。瑞士人寿资产管理有限公司在第三季度将其在再生元制药的持股增加了 112.0%。瑞士人寿资产管理有限公司目前持有 23,658 股生物制药公司的股票，价值 13,302,000 美元，此前在此期间增加了 12,500 股。Cambria Investment Management L.P.在第三季度将其在再生元制药的持股增加了 21.8%。Cambria Investment Management L.P.目前持有 3,090 股生物制药公司的股票，价值 1,737,000 美元，此前在上个季度增加了 554 股。最后，Pointe Capital Management LLC 在第三季度将其在再生元制药的持股增加了 37.0%。Pointe Capital Management LLC 目前持有 719 股生物制药公司的股票，价值 404,000 美元，此前在上个季度增加了 194 股。机构投资者持有公司 83.31% 的股票。</p>
<h2>再生元制药公司简介</h2>
<p>（获取免费报告）</p>
<p>再生元制药公司发现、发明、开发、生产和商业化用于治疗全球各种疾病的药物。公司的产品包括用于治疗湿性年龄相关性黄斑变性和糖尿病性黄斑水肿的 EYLEA 注射剂；近视性脉络膜新生血管；糖尿病视网膜病变；新生血管性青光眼；以及早产儿视网膜病变。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们认为比再生元制药更好的股票</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投资股票</li>
<li>博通在财报后下滑，尽管 AI 需求激增</li>
<li>零售投资者如何交易多伦多证券交易所（TSX）？</li>
<li>高通被称为 AI 失败者——那它为何还在上涨？</li>
<li>交易暂停的解释</li>
<li>2 只小型生物科技公司可能会回报耐心的投资者</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在再生元制药吗？</h2>
<p>在你考虑再生元制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而再生元制药并不在名单上。</p>
<p>尽管再生元制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

再生元制药

<p>摩根士丹利将再生元制药的目标股价从 767.00 美元上调至 768.00 美元，维持 “持平” 评级。其他分析师的评级各不相同，有的给予 “买入” 评级，有的则为 “持有”。该股票目前交易价格为 737.58 美元，市值为 775.2 亿美元。近期注意到内部交易和对冲基金活动，企业内部人士持有该股票的 7.02%</p>

<p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its target price raised by research analysts at Morgan Stanley from $767.00 to $768.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an &#34;equal weight&#34; rating on the biopharmaceutical company's stock. Morgan Stanley's target price points to a potential upside of 4.12% from the company's current price.</p>
<div class="lb-trans"><p>再生元制药（NASDAQ:REGN - 获取免费报告）在摩根士丹利发布的一份研究报告中，将其目标价格从 767.00 美元上调至 768.00 美元。该券商目前对这家生物制药公司的股票给予 “持平” 评级。摩根士丹利的目标价格表明，从公司当前价格来看，潜在上涨幅度为 4.12%。</p>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 个医疗保健股票值得关注，因为行业轮动已全面展开</li>
</ul>
</div><p>A number of other research firms have also recently commented on REGN. Truist Financial initiated coverage on Regeneron Pharmaceuticals in a report on Monday, November 24th. They set a &#34;buy&#34; rating and a $798.00 price target for the company. Weiss Ratings reissued a &#34;hold (c)&#34; rating on shares of Regeneron Pharmaceuticals in a report on Monday. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Monday, November 17th. Guggenheim increased their target price on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, October 29th. Finally, Cantor Fitzgerald raised their price target on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an &#34;overweight&#34; rating in a report on Wednesday, October 29th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $779.45.</p>
<div class="lb-trans"><p>其他一些研究公司也最近对 REGN 发表了评论。Truist Financial 在 11 月 24 日的报告中开始覆盖再生元制药。他们对该公司的评级为 “买入”，目标价格为 798.00 美元。Weiss Ratings 在周一的报告中重新发布了对再生元制药的 “持有（c）” 评级。华尔街 Zen 在 11 月 17 日的报告中将再生元制药的评级从 “持有” 上调至 “买入”。Guggenheim 在 10 月 29 日的研究报告中将再生元制药的目标价格从 815.00 美元上调至 865.00 美元，并给予该公司 “买入” 评级。最后，Cantor Fitzgerald 在 10 月 29 日的报告中将再生元制药的目标价格从 678.00 美元上调至 740.00 美元，并给予该股票 “超配” 评级。三位投资分析师给予该股票 “强烈买入” 评级，十五位分析师给予 “买入” 评级，九位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，再生元制药的共识评级为 “适度买入”，共识目标价格为 779.45 美元。</p>
</div><p><strong>View Our Latest Research Report on REGN</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 REGN 的最新研究报告</strong></p>
</div><h2>Regeneron Pharmaceuticals Trading Down 1.2%</h2>
<div class="lb-trans"><h2>再生元制药股价下跌 1.2%</h2>
</div><ul>
<li>Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>大跌者：3 只接近一年低点的股票，可能在 2025 年大幅上涨</li>
</ul>
</div><p>Regeneron Pharmaceuticals stock traded down $9.22 during midday trading on Friday, hitting $737.58. 233,919 shares of the stock were exchanged, compared to its average volume of 1,096,572. Regeneron Pharmaceuticals has a 52 week low of $476.49 and a 52 week high of $790.98. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $77.52 billion, a PE ratio of 17.66, a P/E/G ratio of 2.08 and a beta of 0.37. The company has a fifty day simple moving average of $661.61 and a two-hundred day simple moving average of $591.76.</p>
<div class="lb-trans"><p>再生元制药的股票在周五的午盘交易中下跌了 9.22 美元，跌至 737.58 美元。该股票的交易量为 233,919 股，而其平均交易量为 1,096,572 股。再生元制药的 52 周低点为 476.49 美元，52 周高点为 790.98 美元。该公司的速动比率为 3.33，流动比率为 4.06，债务股本比率为 0.09。该股票的市值为 775.2 亿美元，市盈率为 17.66，市盈增长比率为 2.08，贝塔值为 0.37。该公司的 50 日简单移动平均线为 661.61 美元，200 日简单移动平均线为 591.76 美元。</p>
</div><p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping the consensus estimate of $9.73 by $2.10. The firm had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company's revenue for the quarter was up .9% on a year-over-year basis. During the same period in the previous year, the company posted $12.46 earnings per share. Equities research analysts anticipate that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>再生元制药（NASDAQ:REGN - 获取免费报告）最近一次发布财报是在 10 月 28 日，生物制药公司报告该季度每股收益为 11.83 美元，超出市场共识预期的 9.73 美元，超出幅度为 2.10 美元。该公司该季度的收入为 37.5 亿美元，而分析师预期为 35.7 亿美元。再生元制药的股本回报率为 13.76%，净利润率为 32.13%。该公司该季度的收入同比增长 0.9%。在去年同期，该公司每股收益为 12.46 美元。股票研究分析师预计再生元制药在当前财政年度将发布 35.92 美元的每股收益。</p>
</div><h2>Insider Transactions at Regeneron Pharmaceuticals</h2>
<div class="lb-trans"><h2>再生元制药的内部交易</h2>
</div><ul>
<li>Best Biotech Stocks to Buy in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年值得购买的最佳生物技术股票</li>
</ul>
</div><p>In related news, Director Christine A. Poon sold 6,500 shares of the business's stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares in the company, valued at $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, VP Jason Pitofsky sold 431 shares of the company's stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares of the company's stock, valued at $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 7.02% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，董事 Christine A. Poon 在 10 月 29 日的交易中出售了 6,500 股公司的股票。该股票的平均售价为 654.27 美元，总交易额为 4,252,755.00 美元。交易完成后，该董事直接持有公司 2,352 股股票，价值 1,538,843.04 美元。此次交易使其持股减少了 73.43%。该交易已在向证券交易委员会的备案中披露，相关信息可通过此链接获取。此外，副总裁 Jason Pitofsky 在 11 月 7 日的交易中出售了 431 股公司的股票。该股票的平均售价为 651.43 美元，总价值为 280,766.33 美元。交易完成后，该副总裁持有公司 4,233 股股票，价值 2,757,503.19 美元。此次交易使其持股减少了 9.24%。该销售的 SEC 备案提供了更多信息。公司内部人士持有公司 7.02% 的股票。</p>
</div><h2>Hedge Funds Weigh In On Regeneron Pharmaceuticals</h2>
<div class="lb-trans"><h2>对再生元制药的对冲基金看法</h2>
</div><p>Several institutional investors and hedge funds have recently made changes to their positions in REGN. Allworth Financial LP lifted its stake in Regeneron Pharmaceuticals by 50.5% in the third quarter. Allworth Financial LP now owns 1,496 shares of the biopharmaceutical company's stock worth $841,000 after purchasing an additional 502 shares during the last quarter. IFP Advisors Inc lifted its stake in shares of Regeneron Pharmaceuticals by 14.2% in the 3rd quarter. IFP Advisors Inc now owns 1,405 shares of the biopharmaceutical company's stock valued at $790,000 after acquiring an additional 175 shares during the last quarter. Swiss Life Asset Management Ltd boosted its holdings in Regeneron Pharmaceuticals by 112.0% during the 3rd quarter. Swiss Life Asset Management Ltd now owns 23,658 shares of the biopharmaceutical company's stock valued at $13,302,000 after acquiring an additional 12,500 shares during the period. Cambria Investment Management L.P. grew its position in Regeneron Pharmaceuticals by 21.8% during the 3rd quarter. Cambria Investment Management L.P. now owns 3,090 shares of the biopharmaceutical company's stock worth $1,737,000 after acquiring an additional 554 shares during the last quarter. Finally, Pointe Capital Management LLC grew its position in Regeneron Pharmaceuticals by 37.0% during the 3rd quarter. Pointe Capital Management LLC now owns 719 shares of the biopharmaceutical company's stock worth $404,000 after acquiring an additional 194 shares during the last quarter. Institutional investors own 83.31% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近对 REGN 的持仓进行了调整。Allworth Financial LP 在第三季度将其在再生元制药的持股增加了 50.5%。Allworth Financial LP 目前持有 1,496 股生物制药公司的股票，价值 841,000 美元，此前在上个季度购买了 502 股。IFP Advisors Inc 在第三季度将其在再生元制药的持股增加了 14.2%。IFP Advisors Inc 目前持有 1,405 股生物制药公司的股票，价值 790,000 美元，此前在上个季度增加了 175 股。瑞士人寿资产管理有限公司在第三季度将其在再生元制药的持股增加了 112.0%。瑞士人寿资产管理有限公司目前持有 23,658 股生物制药公司的股票，价值 13,302,000 美元，此前在此期间增加了 12,500 股。Cambria Investment Management L.P.在第三季度将其在再生元制药的持股增加了 21.8%。Cambria Investment Management L.P.目前持有 3,090 股生物制药公司的股票，价值 1,737,000 美元，此前在上个季度增加了 554 股。最后，Pointe Capital Management LLC 在第三季度将其在再生元制药的持股增加了 37.0%。Pointe Capital Management LLC 目前持有 719 股生物制药公司的股票，价值 404,000 美元，此前在上个季度增加了 194 股。机构投资者持有公司 83.31% 的股票。</p>
</div><h2>Regeneron Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>再生元制药公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.</p>
<div class="lb-trans"><p>再生元制药公司发现、发明、开发、生产和商业化用于治疗全球各种疾病的药物。公司的产品包括用于治疗湿性年龄相关性黄斑变性和糖尿病性黄斑水肿的 EYLEA 注射剂；近视性脉络膜新生血管；糖尿病视网膜病变；新生血管性青光眼；以及早产儿视网膜病变。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Regeneron Pharmaceuticals</li>
<li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li>
<li>Broadcom Slips Post-Earnings Even as AI Demand Goes Parabolic</li>
<li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li>
<li>Qualcomm Just Got Called an AI Loser—So Why Is It Rallying?</li>
<li>Trading Halts Explained</li>
<li>2 Small-Cap Biotechs That Could Reward Patient Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比再生元制药更好的股票</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投资股票</li>
<li>博通在财报后下滑，尽管 AI 需求激增</li>
<li>零售投资者如何交易多伦多证券交易所（TSX）？</li>
<li>高通被称为 AI 失败者——那它为何还在上涨？</li>
<li>交易暂停的解释</li>
<li>2 只小型生物科技公司可能会回报耐心的投资者</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=REGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在再生元制药吗？</h2>
</div><p>Before you consider Regeneron Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑再生元制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而再生元制药并不在名单上。</p>
</div><p>While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管再生元制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

摩根士丹利给予再生元制药（纳斯达克股票代码：REGN）新的目标价为 768.00 美元